First Clinical Trial of GeneTAC Therapy for FA Expected in 2022

First Clinical Trial of GeneTAC Therapy for FA Expected in 2022

311790

First Clinical Trial of GeneTAC Therapy for FA Expected in 2022

Design Therapeutics announced that it remains on track to launch the first clinical trial of its lead experimental candidate — gene-targeted chimera (GeneTAC) — for the treatment of Friedreich’s ataxia (FA) for the first half of 2022. The planned Phase 1 trial will test the therapy in patients, and top-line results are anticipated in the second half of next year. Such development plans are supported by favorable feedback from both the U.S. Food and Drug…

You must be logged in to read/download the full post.